期刊文献+

糖链抗原125在预测卵巢癌复发中的价值 被引量:2

Predictive Value of Carbohydrate Antigen 125 for Recurrence of Ovarian Cancer
下载PDF
导出
摘要 目的评价初诊糖链抗原125(carbohydrate antigen 125,CA125)对卵巢癌复发的预测价值。方法回顾性地从作者医院住院病例库中提取136例初诊卵巢癌患者的国际妇产科协会(Federation International Of GynecologyAnd Obstetrics,FIGO)分期、年龄、病理类型、CA125水平等资料,对患者进行电话随访,获取本研究的观察终点无瘤生存期。采用受试者工作特征曲线(receiver operating characteristic curve,ROC)法、Kaplan-Meier生存曲线法和Cox风险比例模型,分析初诊CA125水平与卵巢癌患者无瘤生存期的关系。结果随访期间复发的83例卵巢癌患者,血清CA125水平明显高于未复发的53例患者。CA125预测卵巢癌复发的曲线下面积(area under the curve,AUC)为0.76(0.68~0.84),最佳预测界值132kU/L,此时的预测敏感度0.71(95%CI:0.60~0.81),特异度0.66(95%CI:0.52~0.78)。CA125≥132kU/L和<132kU/L的卵巢癌的患者无瘤生存期分别为3.1年和4.9年(P<0.01)。在校正了年龄、FIGO分期之后,CA125≥132kU/L仍然与无瘤生存期有关(HR=3.20,P<0.01)。结论CA125可以作为初诊卵巢癌患者术后复发的独立预测因子。 Objective To evaluate the predictive value of carbohydrate antigen 125(CA125) for the recurrence of ovarian cancer.Methods The medical records,including age,Federation International Of Gynecology And Obstetrics(FIGO) stages and CA125 levels were retrospectively extracted from 136 patients with newly diagnosed ovarian cancer.All these patients were followed up by telephone interview to obtain the data of ovarian cancer free survival,the endpoint of this study.Receiver operating characteristic curve analysis,Kaplan-Meier approach and Cox model were used to analyze the relationship between CA125 level and the ovarian cancer free survival.Results Increased serum CA125 was observed in 83 patients with ovarian cancer recurrence during the follow up.The area under curve(AUC) of serum CA125 was 0.76(95% CI:0.68-0.84),with the predictive sensitivity of 0.71(95% CI:0.60-0.81) and specificity of 0.66(95% CI:0.52-0.78) at the optimal threshold of 132 kU/L.The median ovarian cancer free survival for patients with increased(CA125≥132 kU/L) and decreased(CA125132 kU/L) CA125 were 3.1 and 4.9 years respectively(P0.01).After correction for age and FIGO stages,CA125≥132 kU/L was independently associated with the recurrence of ovarian cancer(HR=3.20,P0.01).Conclusion In patients with newly diagnosed ovarian cancer,CA125 is an independent predictor for recurrence.
出处 《华南国防医学杂志》 CAS 2012年第5期452-454,463,共4页 Military Medical Journal of South China
关键词 糖链抗原125 卵巢癌 复发 Carbohydrate antigen 125 Ovarian cancer Recurrence
  • 相关文献

参考文献14

  • 1Cannistra SA. Cancer of the ovary[[J]. N Engl J Med, 2004,351 (24) :2519-2529.
  • 2Gadducci A, Cosio S, Conte PF, et al. Consolidation and mainte nance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy:a review of the literature[J ]. Crit Rev Oncol Hematol, 2005,55 ( 2 ) : 153- 166.
  • 3Miller RE, Rustin GJ. How to follow-up patients with epithelia ovarian cancer[J]. CurrOpin Oncol, 2010,22 (5) : 498-502.
  • 4Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer European Group on Tumor Markers guidelines for clinical use[[J]. Int J Gynecol Cancer,2005,15(5):679- 691.
  • 5Medeiros LR, Rosa DD, da Rosa MI, et al. Accuracy of CA /25 in the diagnosis of ovarian tumors: a quantitative systematic re- vicw[J]. Eur J Obstet Gynecol Reprod Biol,2009,142(2):99 1(15.
  • 6Fures R, Bukovic D, Bukovic D, et al. Preoperative tumor mark- er CA125 levels in relation to epithelial ovarian cancer stage[[J]. Coil Antropo], 1999,23( 1 ) : 189 -194.
  • 7MontaRnana M, Lippi G, Ruzzenente O, etal. The utility of ser unl human cpididymis protein 4(HE4) in patients with a pelvic tuass[J ]. J Clin Lab Anal,2009,23(5) :331-335.
  • 8蓝春燕,黄鹤,刘继红.晚期卵巢上皮性癌患者初次治疗过程中血清CA125水平变化与其预后的关系[J].中华妇产科杂志,2008,43(10):732-736. 被引量:7
  • 9王新宇,叶菁,冯素文,吕卫国,万小云,谢幸.血清CA125水平测定在预测卵巢上皮性癌复发和预后中的价值[J].中华妇产科杂志,2010,45(11):813-816. 被引量:28
  • 10Kang S, Seo SS, Park SY. Nadir CA125 level is an independent prognostic factor in advanced epithelial ovarian cancer[[J]. J Surg Oncol, 2009,100(3) :244-247.

二级参考文献26

  • 1陈艳,叶大风,谢幸.血清CA125测定在上皮性卵巢癌病情监测中的作用[J].国外医学(计划生育分册),2005,24(2):90-94. 被引量:6
  • 2Piccart M J, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer : three-year resuhs. J Nail Cancer lnst,2000,92:699-708.
  • 3Brun JL, Feyler A, Chene G, et al. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol 0ncol,2000,78:21-27.
  • 4Markman M, Bundy BN, Alberts DS, et al. Phase Ⅲ trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smaU-volume stage Ⅲ ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Onco1,2001,19 : 1001-1007.
  • 5Bast RC Jr, Klug TL, St John E,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med,1983,309:883-887.
  • 6Kenemans P, Yedema CA, Bon GG, et al. CA125 in gynecological pathology: a review. Eur J Obstet Gynecol Reprod Biol, 1993,49 : 115-124.
  • 7Cooper BC, Sood AK, Davis CS, et al. Preoperative CA125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol,2002,100:59-64.
  • 8van Dalen A, Favier J, Burges A, et al. Prognostic significance of CA125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol,2000,79:444-450.
  • 9Markman M, Federico M, Liu PY, et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol,2006,103:195-198.
  • 10Colakovic S, Lukic V, Mitrovic L, et al. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers ,2000,15 : 147-152.

共引文献75

同被引文献22

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部